Cargando…

Effects of mild and moderate renal dysfunction on pharmacokinetics, pharmacodynamics, and safety of dotinurad: a novel selective urate reabsorption inhibitor

BACKGROUND: Dotinurad, a novel selective urate reabsorption inhibitor, exerts a serum uric acid-lowering effect by selectively inhibiting urate transporter 1 (URAT1) in patients with hyperuricemia. It is generally known that the progression of renal dysfunction is associated with a reduction in the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fukase, Hiroyuki, Okui, Daisuke, Sasaki, Tomomitsu, Fushimi, Masahiko, Ohashi, Tetsuo, Hosoya, Tatsuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066277/ https://www.ncbi.nlm.nih.gov/pubmed/31823130 http://dx.doi.org/10.1007/s10157-019-01825-3

Ejemplares similares

The effect for hyperuricemia inpatient of uric acid overproduction type or in combination with topiroxostat on the pharmacokinetics, pharmacodynamics and safety of dotinurad, a selective urate reabsorption inhibitor
por: Okui, Daisuke, et al.
Publicado: (2019)

Open-label study of long-term administration of dotinurad in Japanese hyperuricemic patients with or without gout
por: Hosoya, Tatsuo, et al.
Publicado: (2019)

Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study
por: Hosoya, Tatsuo, et al.
Publicado: (2019)

Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 study
por: Hosoya, Tatsuo, et al.
Publicado: (2019)

Clinical pharmacological study of dotinurad administered to male and female elderly or young subjects
por: Nakatani, Hiroshi, et al.
Publicado: (2019)

A clinical pharmacology study of the novel, selective urate reabsorption inhibitor dotinurad in outpatients
por: Hosoya, Tatsuo, et al.
Publicado: (2020)

Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study
por: Hosoya, Tatsuo, et al.
Publicado: (2020)

A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout
por: Hosoya, Tatsuo, et al.
Publicado: (2020)

Comparative study of a novel selective urate reabsorption inhibitor “dotinurad” among patient groups with different stages of renal dysfunction
por: Takahashi, Toshinari, et al.
Publicado: (2021)

Dotinurad: a clinical pharmacokinetic study of a novel, selective urate reabsorption inhibitor in subjects with hepatic impairment
por: Kumagai, Yuji, et al.
Publicado: (2019)

Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia
por: Kuriyama, Satoru
Publicado: (2019)

Pharmacokinetic/pharmacodynamic modeling and simulation of dotinurad, a novel uricosuric agent, in healthy volunteers
por: Motoki, Keisuke, et al.
Publicado: (2019)

Clinical effects of a selective urate reabsorption inhibitor dotinurad in patients with hyperuricemia and treated hypertension: a multicenter, prospective, exploratory study (DIANA)
por: Tanaka, Atsushi, et al.
Publicado: (2023)

Efficacy and safety of switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor, in hyperuricemic patients with type 2 diabetic kidney disease: Protocol for a single-arm, open-label, prospective, exploratory study
por: Osonoi, Takeshi, et al.
Publicado: (2023)

A drug–drug interaction study of a novel, selective urate reabsorption inhibitor dotinurad and the non-steroidal anti-inflammatory drug oxaprozin in healthy adult males
por: Furihata, Kenichi, et al.
Publicado: (2020)

Clinical efficacy and safety of topiroxostat in Japanese hyperuricemic patients with or without gout: a randomized, double-blinded, controlled phase 2b study
por: Hosoya, Tatsuo, et al.
Publicado: (2016)

URAT1 is expressed in cardiomyocytes and dotinurad attenuates the development of diet-induced metabolic heart disease
por: Tanaka, Yoshiro, et al.
Publicado: (2023)

A Possible Exquisite Crosstalk of Urate Transporter 1 With Other Urate Transporters for Chronic Kidney Disease and Cardiovascular Disease Induced by Dotinurad
por: Yanai, Hidekatsu, et al.
Publicado: (2023)

Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout
por: Terkeltaub, Robert, et al.
Publicado: (2019)

Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Verinurad, a Selective Uric Acid Reabsorption Inhibitor
por: Smith, William B., et al.
Publicado: (2018)

Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment
por: Frost, Charles E., et al.
Publicado: (2021)

Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males
por: Shen, Zancong, et al.
Publicado: (2015)

SLC2A9 (GLUT9) mediates urate reabsorption in the mouse kidney
por: Auberson, Muriel, et al.
Publicado: (2018)

Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects
por: Shen, Zancong, et al.
Publicado: (2017)

Enteric reabsorption processes and their impact on drug pharmacokinetics
por: Ibarra, Manuel, et al.
Publicado: (2021)

Evaluation of the Pharmacokinetics and Pharmacodynamics of Prasugrel in Japanese Elderly Subjects
por: Hasunuma, Tomoko, et al.
Publicado: (2017)

Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese and non-Asian male subjects
por: Hall, Jesse, et al.
Publicado: (2018)

Safety, tolerability, pharmacokinetics and pharmacodynamics of belimumab in Japanese patients with mild-to-moderate systemic lupus erythematosus
por: Yamada, Masanori, et al.
Publicado: (2013)

Pharmacokinetics, pharmacodynamics, and safety of clevidipine after prolonged continuous infusion in subjects with mild to moderate essential hypertension
por: Smith, William B., et al.
Publicado: (2012)

Population Pharmacokinetics and Pharmacodynamics of the Neutralizing Antibodies Bamlanivimab and Etesevimab in Patients With Mild to Moderate COVID‐19 Infection
por: Chigutsa, Emmanuel, et al.
Publicado: (2021)

In Vitro and In Vivo Interaction Studies Between Lesinurad, a Selective Urate Reabsorption Inhibitor, and Major Liver or Kidney Transporters
por: Shen, Zancong, et al.
Publicado: (2016)

Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer’s disease
por: Yoshida, Kenta, et al.
Publicado: (2020)

Evaluation of Pharmacokinetic and Pharmacodynamic Drug–Drug Interaction of Sacubitril/Valsartan (LCZ696) and Sildenafil in Patients With Mild‐to‐Moderate Hypertension
por: Hsiao, H‐L, et al.
Publicado: (2017)

The impact of genetic variability in urate transporters on oxypurinol pharmacokinetics
por: Hishe, Hailemichael Z., et al.
Publicado: (2022)

FILTRATION AND REABSORPTION OF PROTEIN BY THE KIDNEY
por: Sellers, Alvin L., et al.
Publicado: (1954)

Reabsorption of fast secondaries in nuclei
por: Von Behr, J, et al.
Publicado: (1961)

Pharmacokinetics and Pharmacodynamics of Posaconazole
por: Chen, Lu, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Ibrexafungerp
por: McCarthy, Matthew William
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Tedizolid
por: Iqbal, Khalid, et al.
Publicado: (2022)

Circulating FABP4 is eliminated by the kidney via glomerular filtration followed by megalin-mediated reabsorption
por: Shrestha, Suman, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_sfgif7au55npo1b5cadi2dol5l